US FDA adds warning on Johnson & Johnson COVID-19 vaccine related to rare neurological disorder

Guillain Barre syndrome is a neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis, the FDA said on Monday.

The syndrome has occurred in some people who have received the Johnson & Johnson vaccine. In most of these people, symptoms began within 42 days following injections of the vaccine, said the FDA in a letter.

The chance of having this occur is very low, the agency said.

About 100 preliminary reports of Guillain-Barre syndrome have been detected in vaccine recipients after the administration of 12.8 million doses of the Johnson & Johnson vaccine in the United States, The Washington Post quoted the U.S. Centers for Disease Control and Prevention (CDC) as saying in a statement.

Of these reports, 95 were serious and required hospitalization, and one was dead.

The cases have largely been reported about two weeks after vaccination and mostly in men, many aged 50 and older, according to the CDC.

Johnson & Johnson said Monday it has been in discussions with the FDA and other regulators about rare cases of Guillain-Barre syndrome.

The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree, the company said in a statement.